Page last updated: 2024-12-06
dialifor
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
dialifor: insecticide [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 25146 |
| CHEMBL ID | 1901826 |
| CHEBI ID | 82158 |
| SCHEMBL ID | 122099 |
| MeSH ID | M0044663 |
Synonyms (66)
| Synonym |
|---|
| phosphorodithioic acid, s-(2-chloro-1-phthalimidoethyl) o,o-diethyl ester |
| o,o-diaethyl-s-2-chlor-1-(phthalimido)-aethyl-dithiophosphat [german] |
| brn 1550800 |
| caswell no. 280a |
| dialifos |
| einecs 233-689-3 |
| dialifor [ansi:bsi:iso] |
| hsdb 1559 |
| dialiphos |
| n-(2-chloro-1-(diethoxyphosphinothioylthio)ethyl)phthalimide |
| s-(2-chloro-1-(1,3-dihydro-1,3-dioxo-2h-isoindol-2-yl)ethyl) o,o-diethyl phosphorodithioate |
| o,o-diethyl s-(2-chloro-1-phthalimidoethyl)phosphorodithioate |
| s-(2-chloro-1-(1,3-dihydro-1,3-dioxo-2h-isoindol-2-yl)ethyl)o,o-diethyl phosphorodithioate |
| epa pesticide chemical code 102501 |
| o,o-diethyl phosphorodithioate s-ester with n-(2-chloro-1-mercaptoethyl) phthalimide |
| ai3-27320 |
| dialiphos [iso-french] |
| o,o-diethyl phosphorodithioate s-ester with n-(2-chloro-1-mercaptoethyl)phthalimide |
| phosphorodithioic acid, o,o-diethyl ester, s-ester with n-(2-chloro-1-mercaptoethyl)phthalimide |
| s-(2-chloro-1-phthalimidoethyl) o,o-diethyl phosphorodithioate |
| dialiphor |
| torak |
| phosphorodithioic acid, s-(2-chloro-1-(1,3-dihydro-1,3-dioxo-2h-isoindol-2-yl)ethyl) o,o-diethyl ester |
| s-(2-chloro-1-phthalmidoethyl)-o,o-diethylphosphorothionate |
| phosphorodithioic acid, s-(2-chloro-1-phthalimidoethyl)-o,o-diethyl ester |
| hercules 14503 |
| ent 27320 |
| phosphorodithioic acid, s-[2-chloro-1-(1,3-dihydro-1,3-dioxo-2h-isoindol-2-yl)ethyl] o,o-diethyl ester |
| dialifor |
| NCGC00160634-01 |
| NCGC00160634-02 |
| 2-(2-chloro-1-diethoxyphosphinothioylsulfanylethyl)isoindole-1,3-dione |
| NCGC00160634-03 |
| C19028 |
| 10311-84-9 |
| 8480k0vb4e , |
| unii-8480k0vb4e |
| o,o-diaethyl-s-2-chlor-1-(phthalimido)-aethyl-dithiophosphat |
| NCGC00254698-01 |
| dtxsid0037522 , |
| dtxcid8017522 |
| tox21_300794 |
| cas-10311-84-9 |
| SCHEMBL122099 |
| CHEBI:82158 , |
| CHEMBL1901826 |
| MUMQYXACQUZOFP-UHFFFAOYSA-N |
| s-[2-chloro-1-(1,3-dioxo-1,3-dihydro-2h-isoindol-2-yl)ethyl] o,o-diethyl dithiophosphate # |
| o,o-diethyl phosphorodithioate s-ester with n-(2-chloro-1- mercaptoethyl)phthalimide |
| phosphorodithioic acid, o,o-diethyl ester, s-ester with n- (2-chloro-1-mercaptoethyl)phthalimide |
| phosphorodithioic acid, s-(2-chloro-1-phthalimidoethyl) o,o- diethyl ester |
| phosphorodithioic acid, s-(2-chloro-1-phthalimidoethyl)-o,o- diethyl ester |
| dialifor [iso] |
| phthalimide, n-(2-chloro-1-mercaptoethyl)-, s-ester with o,o-diethyl phosphorodithioate |
| s-(2-chloro-1-(1,3-dihydro-1,3-dioxo-2h-isoindol-2- yl)ethyl) o,o-diethyl phosphorodithioate |
| dialifor [mi] |
| o,o-diethyl phosphorodithioate s-ester with n-(2-chloro-1- mercaptoethyl) phthalimide |
| phosphorodithioic acid, s-(2-chloro-1-(1,3-dihydro-1,3- dioxo-2h-isoindol-2-yl)ethyl) o,o-diethyl ester |
| o,o-diethyl s-(2-chloro-1- phthalimidoethyl)phosphorodithioate |
| dialifos [hsdb] |
| J-000876 |
| dialifos, pestanal(r), analytical standard |
| dialifos 10 microg/ml in cyclohexane |
| s-2-chloro-1-(1,3-dioxoisoindolin-2-yl)ethyl o,o-diethyl phosphorodithioate |
| Q5270555 |
| phosphorodithioic acid s-[2-chloro-1-(1,3-dihydro-1,3-dioxo-2h-isoindol-2-yl)ethyl] o,o-diethyl ester |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (1)
| Class | Description |
|---|---|
| isoindoles | |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Protein Targets (24)
Potency Measurements
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| acetylcholinesterase | Homo sapiens (human) | Potency | 26.6022 | 0.0025 | 41.7960 | 15,848.9004 | AID1347395; AID1347397; AID1347398; AID1347399 |
| pregnane X receptor | Rattus norvegicus (Norway rat) | Potency | 25.1189 | 0.0251 | 27.9203 | 501.1870 | AID651751 |
| RAR-related orphan receptor gamma | Mus musculus (house mouse) | Potency | 54.4827 | 0.0060 | 38.0041 | 19,952.5996 | AID1159523 |
| GLI family zinc finger 3 | Homo sapiens (human) | Potency | 43.2771 | 0.0007 | 14.5928 | 83.7951 | AID1259369; AID1259392 |
| AR protein | Homo sapiens (human) | Potency | 54.3546 | 0.0002 | 21.2231 | 8,912.5098 | AID1259243; AID1259247; AID743035; AID743042; AID743054; AID743063 |
| estrogen receptor 2 (ER beta) | Homo sapiens (human) | Potency | 30.6379 | 0.0006 | 57.9133 | 22,387.1992 | AID1259378 |
| nuclear receptor subfamily 1, group I, member 3 | Homo sapiens (human) | Potency | 30.6379 | 0.0010 | 22.6508 | 76.6163 | AID1224839 |
| progesterone receptor | Homo sapiens (human) | Potency | 27.3060 | 0.0004 | 17.9460 | 75.1148 | AID1346795 |
| glucocorticoid receptor [Homo sapiens] | Homo sapiens (human) | Potency | 54.9410 | 0.0002 | 14.3764 | 60.0339 | AID720692 |
| retinoic acid nuclear receptor alpha variant 1 | Homo sapiens (human) | Potency | 53.0504 | 0.0030 | 41.6115 | 22,387.1992 | AID1159552; AID1159555 |
| retinoid X nuclear receptor alpha | Homo sapiens (human) | Potency | 6.5694 | 0.0008 | 17.5051 | 59.3239 | AID1159531; AID588544 |
| estrogen-related nuclear receptor alpha | Homo sapiens (human) | Potency | 38.7216 | 0.0015 | 30.6073 | 15,848.9004 | AID1224848; AID1224849; AID1259403 |
| pregnane X nuclear receptor | Homo sapiens (human) | Potency | 24.4980 | 0.0054 | 28.0263 | 1,258.9301 | AID1346982; AID720659 |
| estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 39.1932 | 0.0002 | 29.3054 | 16,493.5996 | AID588514; AID743069; AID743075; AID743077; AID743078; AID743079; AID743080 |
| peroxisome proliferator-activated receptor delta | Homo sapiens (human) | Potency | 61.6448 | 0.0010 | 24.5048 | 61.6448 | AID743215 |
| peroxisome proliferator activated receptor gamma | Homo sapiens (human) | Potency | 39.8107 | 0.0010 | 19.4141 | 70.9645 | AID588536 |
| aryl hydrocarbon receptor | Homo sapiens (human) | Potency | 12.9199 | 0.0007 | 23.0674 | 1,258.9301 | AID743122 |
| thyroid stimulating hormone receptor | Homo sapiens (human) | Potency | 68.5896 | 0.0016 | 28.0151 | 77.1139 | AID1259395 |
| nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_a | Homo sapiens (human) | Potency | 61.6448 | 19.7391 | 45.9784 | 64.9432 | AID1159509 |
| Histone H2A.x | Cricetulus griseus (Chinese hamster) | Potency | 80.0009 | 0.0391 | 47.5451 | 146.8240 | AID1224845 |
| thyroid hormone receptor beta isoform 2 | Rattus norvegicus (Norway rat) | Potency | 74.8063 | 0.0003 | 23.4451 | 159.6830 | AID743065; AID743067 |
| heat shock protein beta-1 | Homo sapiens (human) | Potency | 13.8006 | 0.0420 | 27.3789 | 61.6448 | AID743210 |
| nuclear factor erythroid 2-related factor 2 isoform 1 | Homo sapiens (human) | Potency | 25.2914 | 0.0006 | 27.2152 | 1,122.0200 | AID651741; AID720636; AID743202; AID743219 |
| Cellular tumor antigen p53 | Homo sapiens (human) | Potency | 68.5896 | 0.0023 | 19.5956 | 74.0614 | AID651631; AID720552 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Biological Processes (124)
Molecular Functions (34)
Ceullar Components (19)
Research
Studies (5)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 3 (60.00) | 18.7374 |
| 1990's | 2 (40.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 19.94
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (19.94) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 1 (14.29%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (85.71%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||